ERBB2 and neoplasm: OMVs engineered to display a ClyA‐HER2 targeting probe were able to target cells over‐expressing HER2, a common biomarker of cancer cells, and induce cell death and tumor shrinkage via the delivery of siRNA targeting the expression of kinesin spindle protein (Gujrati et al., 2014).